US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Enzymatica conducts a directed issue totalling SEK 19 million

The biotech company, Enzymatica, successfully completed a directed issue yesterday, raising around SEK 19 million before deducting issue expenses, under the authority of a resolution of the annual general meeting held on 6 May. The capital raised will be used primarily in the launch of the new treatment for the common cold, ColdZyme® Mouth Spray, on the Swedish market, and to finance the Company’s on-going research and product development work. At the annual general meeting held on 6 May, the Board was authorised, at its own discretion, to issue a maximum of 2,000,000 new shares with or

Broad launch for ColdZyme® Mouth Spray, soon on Apoteket AB’s shelves

The biotech company Enzymatica has signed an agreement with Apoteket AB, Sweden’s largest pharmacy chain. From early September, Enzymatica’s cold treatment product, ColdZyme® Mouth Spray, will be on sale at Apoteket AB. As of early September, Enzymatica’s registered medical device product against the common cold, ColdZyme® Mouth Spray, will form part of the regular range stocked by Apoteket AB and will be available from outlets throughout Sweden. The launch coincides with the beginning of the usual cold season, i.e. the end of the summer holidays and the start of the school year. - We

Enzymatica signs agreement with Actavis for ColdZyme in the Nordic region

Enzymatica and the international pharmaceuticals company, Actavis, have signed a letter of intent on the sale of Enzymatica’s cold treatment product, ColdZyme® Mouth Spray, on the Nordic market. Under the agreement, ColdZyme Mouth Spray will be on sale in around 3,200 pharmacies and a large number of stores, including health food retailers, in the Nordic region. Under the letter of intent, Actavis ColdZyme Mouth spray will be licensed for distribution and sale in Sweden, Denmark, Finland, Norway and Iceland. Actavis anticipates launching ColdZyme for sale in Sweden during the second half

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe